Coherus Oncology: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Nov. 9, 2026, Coherus Oncology (CHRS +6.18%) announced a 30% workforce cut to lower operating expenses while focusing development on its primary cancer drug candidates. The business faces a cash runway of less than 12 months, making spending discipline and sales execution vital for long-term survival. Three things management said stand out.

1. Headcount Cuts Lower Quarterly Revenue Required for Cash Breakeven

Management is cutting workforce from about 140 to 100 full-time employees, or FTEs, this month to streamline operations after exiting its biosimilar business. This rightsizing trims quarterly costs by $6 million to $7 million, lowering the revenue LOQTORZI, its approved cancer drug, needs to cover nondevelopment core cash burn from $30 million to $35 million down to $25 million to $30 million per quarter.

These savings will come primarily from an approximately 30% reduction in headcount from about 140 to 100 FTEs, which will take place this month.
— Bryan McMichael, Chief Financial Officer

2. Clinical Focus Shifts to Second-Line Esophageal Cancer Trials

Coherus Oncology is narrowing clinical efforts for tagmokitug, its clinical-stage targeted antibody candidate, toward esophageal cancer to create a faster regulatory path. Early trial results in combination with toripalimab demonstrated responses in both main tumor cell types, establishing a go-forward dose of 700 milligrams for upcoming U.S. Food and Drug Administration discussions.

In this setting, we demonstrated activity in both squamous and adeno histologies at the go-forward dose of 700 milligrams tagmokitug with toripalimab.
— Rosh Dias, Chief Medical Officer

3. Oncologist Adoption Drives LOQTORZI Market Share Expansion Goals

Net sales of LOQTORZI reached $14 million in the third quarter, representing 25% year-over-year growth despite sequential lumpiness. A recent survey showed three out of four oncologists now view the drug as standard treatment for nasopharyngeal carcinoma, or NPC, a rare head and neck cancer, compared to under 35% favoring off-label immuno-oncology therapies, or IOs.

75% of surveyed oncologists now view LOQTORZI as the standard of care in NPC compared with fewer than 35% who hold a similar view for off-label IOs.
— Sameer Goregaoker, Chief Commercial Officer

Looking Ahead

Commercial adoption is accelerating across key oncology accounts, supporting a path toward cash balance stability. High adoption rates among oncologists and established payer preferences provide structural advantages as sales expand. Management is watching physician prescribing habits, patient start consistency, and regulatory alignment for tagmokitug.

We’re going to drive the commercial sales toward core burn breakeven as quickly as possible in 2027.
— Denny Lanfear, Chief Executive Officer

Financial runway protection remains the overarching operational priority while clinical development advances. International partnering opportunities and reduced operating expenses offer capital flexibility without equity dilution.

And we’ll pursue nondilutive funding options, including ex-U.S. partnering transactions.
— Denny Lanfear, Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.